Omeros Corporation (NASDAQ:OMER) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.12, Morningstar.com reports. The company had revenue of $17.15 million for the quarter, compared to analyst estimates of $14.63 million. The company’s quarterly revenue was up 71.5% on a year-over-year basis. During the same period last year, the business earned ($0.32) EPS.

Shares of Omeros Corporation (NASDAQ OMER) opened at 21.72 on Wednesday. The firm’s market cap is $954.36 million. The company has a 50 day moving average of $21.81 and a 200 day moving average of $15.66. Omeros Corporation has a 1-year low of $7.20 and a 1-year high of $27.09.

In other Omeros Corporation news, VP Michael A. Jacobsen sold 24,000 shares of the stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $21.20, for a total value of $508,800.00. Following the completion of the sale, the vice president now owns 2,650 shares in the company, valued at $56,180. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Michael A. Jacobsen sold 12,000 shares of the stock in a transaction on Friday, June 16th. The shares were sold at an average price of $24.95, for a total transaction of $299,400.00. Following the completion of the sale, the vice president now owns 19,500 shares of the company’s stock, valued at approximately $486,525. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Nwam LLC boosted its stake in shares of Omeros Corporation by 0.5% in the first quarter. Nwam LLC now owns 44,790 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 232 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Omeros Corporation by 7.8% in the second quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after buying an additional 751 shares in the last quarter. Rhumbline Advisers boosted its stake in Omeros Corporation by 1.8% in the second quarter. Rhumbline Advisers now owns 46,632 shares of the biopharmaceutical company’s stock worth $928,000 after buying an additional 832 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Omeros Corporation by 5.5% in the first quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 1,960 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in Omeros Corporation by 1.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 197,665 shares of the biopharmaceutical company’s stock worth $3,935,000 after buying an additional 2,548 shares in the last quarter. Hedge funds and other institutional investors own 45.11% of the company’s stock.

OMER has been the subject of a number of research reports. Cantor Fitzgerald lowered shares of Omeros Corporation from a “buy” rating to a “neutral” rating and decreased their target price for the company from $21.00 to $15.00 in a research note on Thursday, May 11th. Maxim Group set a $23.00 price objective on shares of Omeros Corporation and gave the company a “buy” rating in a research note on Thursday, May 11th. Wedbush reaffirmed an “outperform” rating and issued a $47.00 price objective on shares of Omeros Corporation in a research note on Wednesday, May 10th. ValuEngine raised shares of Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cowen and Company reaffirmed an “outperform” rating on shares of Omeros Corporation in a research note on Saturday, June 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $32.80.

COPYRIGHT VIOLATION WARNING: “Omeros Corporation (OMER) Releases Earnings Results” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/08/08/omeros-corporation-nasdaqomer-issues-quarterly-earnings-results.html.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Earnings History for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.